Last reviewed 2026-04-23 · How we verify

HS-10234

HS-10234 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.

HS-10234 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers).

At a glance

Mechanism of action

HS-10234 targets FGFR mutations and fusions that drive proliferation in certain solid tumors. By inhibiting FGFR kinase activity, the drug suppresses downstream signaling pathways critical for tumor cell survival and growth. This mechanism is particularly relevant in cancers with FGFR alterations, including cholangiocarcinoma and other FGFR-driven malignancies.

Approved indications

• FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers)

Common side effects

• Hyperphosphatemia
• Diarrhea
• Fatigue
• Nausea
• Stomatitis

Key clinical trials

• Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB (PHASE4)
• Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection (PHASE3)
• Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HS-10234 CI brief — competitive landscape report
• HS-10234 updates RSS · CI watch RSS
• Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI